Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin
Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. Data also support the clinical benefit of combination antiviral therapy in pat...
Saved in:
Main Authors: | Morris Sherman, Lawrence Cohen, Mary Anne Cooper, Magdy Elkashab, Victor Feinman, David Fletcher, Nigel Girgrah, Jenny Heathcote, Mark Levstik, William B McNaull, David Wong, Florence Wong, Colina Yim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2006-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2006/497059 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C
by: David N Moskovitz, et al.
Published: (2003-01-01) -
Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats
by: Xiaohan Cao, et al.
Published: (2014-01-01) -
Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada)
by: Robert P Myers, et al.
Published: (2011-01-01) -
Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
by: Louis WC Liu, et al.
Published: (2003-01-01) -
Cirrhotic Cardiomyopathy: Does it Contribute to Chronic Fatigue and Decreased Health-Related Quality of Life in Cirrhosis?
by: Nigel Girgrah, et al.
Published: (2003-01-01)